FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Meyer Colin John		 2. Issuer Name and Ticker or Trading Symbol

REATA PHARMACEUTICALS INC [ RETA ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Innovation Officer
(Last)          (First)          (Middle)

5320 LEGACY DRIVE		 3. Date of Earliest Transaction (MM/DD/YYYY)

2/28/2023
(Street)

PLANO, TX 75024
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A common stock 2/28/2023  A  15000 (1)A$0.00 90513 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right-to-buy) $27.32 2/28/2023  A   30000     (2)1/3/2032 Class A common stock 30000 $0.00 30000 D  
Explanation of Responses:
(1) The shares represent Restricted Stock Units granted with performance criteria (PSUs). On January 2, 2021, the reporting person was granted 15,000 PSUs. On February 28, 2023, based on the satisfaction of certain performance criteria, the PSUs vested as to 6,563 shares and is set to vest one quarter of 11,250 shares on March 31, 2023; June 30, 2023, and September 30, 2023, subject to continued service through each vesting date.
(2) On January 3, 2022, the reporting person was granted an option to purchase 30,000 shares of Class A common stock. On February 28, 2023 based on the satisfaction of certain performance criteria, the option vested as to 13,125 shares and is set to vest 5,625 shares on March 31, 2023; June 30, 2023, and September 30, 2023, subject to continued service through each vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Meyer Colin John
5320 LEGACY DRIVE
PLANO, TX 75024

Chief Innovation Officer
Signatures
/s/ Tracy Herson, attorney-in-fact3/1/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Reata Pharmaceuticals Charts.
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Reata Pharmaceuticals Charts.